David Nierengarten

Managing Director, Equity Research at Wedbush Securities
On the record
Represented by:
Bio

David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.

COMPANIES UNDER COVERAGE
AnaptysBio, Inc. (ANAB)
Applied Genetic
Technologies Corp (AGTC)
arGEN-X SE (ARGX)
AVROBIO, Inc. (AVRO US)
Beam therapeutice (BEAM)
bluebird bio (BLUE)
Blueprint Medicines Corp (BPMC)
Chimerix Inc. (CMRX)
Codiak BioSciences (CDAK)
Epizyme Inc. (EPZM)
Fate Therapeutics (FATE)
Fennec Pharma (FENC)
Freeline TherapeuticesHoldings PLC (FRLN)
Fusion Pharmaceuticals (FUSN)
G1 Therapeutics Inc. (GTHX)
Generation Bio Co (GBIO)
Intellia Therapeutics (NTLA)
Inozyme Pharma (INZY)
iTeos Therapeutics Inc. (ITOS)
Iveric Bio Inc. (ISEE)
Karyopharm Therapeutics (KPTI)
Kiniksa Pharmaceuticals (KNSA)
Kinnate Biopharma (KNTE)
MacroGenics (MGNX)
Magenta Therapeutics (MGTA)
Mersana Therapeutics (MRSN)
NovoCure Ltd. (NVCR)
Nuvation Bio (NUVB)
Orchard Therapeutics (ORTX)
Scholar Rock (SRRK)
Springworks Therapeutics Inc. (SWTX)
Sutro Biopharma (STRO)
TCR2 Therapeutics Inc. (TCRR)
Turning Point Inc (TPTX)
Xencor (XNCR)
Y-mAbs Therapeutics, Inc. (YMAB)

Recent Quotes
Sign up to view all
  • Approval marks a favorable ending to a roller coaster regulatory ride, although regulatory risk remains.

    29 July 2019
  • If Orchard could decentralize the process, then you would have a viable commercial product.

    8 July 2019
  • Approval marks a favorable ending to a roller coaster regulatory ride, although regulatory risk remains.

    8 July 2019
Employment
Sign up to view all